Published in Urology on February 01, 2001
Regulation of microtubule, apoptosis, and cell cycle-related genes by taxotere in prostate cancer cells analyzed by microarray. Neoplasia (2004) 0.92
Aqueous Extract of Solanum nigrum Leaf Activates Autophagic Cell Death and Enhances Docetaxel-Induced Cytotoxicity in Human Endometrial Carcinoma Cells. Evid Based Complement Alternat Med (2012) 0.88
Growth Arrest-Specific 6 (GAS6) Promotes Prostate Cancer Survival by G1 Arrest/S Phase Delay and Inhibition of Apoptosis During Chemotherapy in Bone Marrow. J Cell Biochem (2016) 0.79
Findings of scientific misconduct. NIH Guide Grants Contracts (2002) 0.75
Delineation of prognostic biomarkers in prostate cancer. Nature (2001) 12.25
Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res (2000) 3.71
Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology (1997) 3.61
VCaP, a cell-based model system of human prostate cancer. In Vivo (2001) 3.36
Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst (1998) 2.83
The role of the nuclear matrix in the organization and function of DNA. Annu Rev Biophys Biophys Chem (1986) 2.07
Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol (2000) 1.97
Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology (1999) 1.92
A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology (1998) 1.69
E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum Pathol (2001) 1.68
The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia (2008) 1.60
Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res (2000) 1.54
Retracted Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha "super-repressor". Clin Cancer Res (2000) 1.46
A structural analysis of the role of the nuclear matrix and DNA loops in the organization of the nucleus and chromosome. J Cell Sci Suppl (1984) 1.43
Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev (2001) 1.41
Identification of nuclear matrix proteins in the cancer and normal rat prostate. Cancer Res (1991) 1.35
Parathyroid hormone-related protein as a growth regulator of prostate carcinoma. Cancer Res (1999) 1.24
Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol (1998) 1.22
Nuclear structure and the three-dimensional organization of DNA. J Cell Biochem (1991) 1.16
Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a minireview. Prostate Cancer Prostatic Dis (2000) 1.12
Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology (1994) 1.07
Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol (1999) 1.07
Decreased galectin-3 expression in prostate cancer. Prostate (2000) 1.07
Early castration reduces prostatic carcinogenesis in transgenic mice. Urology (1999) 1.07
The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis. BMC Cancer (2006) 1.04
Paclitaxel in the treatment of hormone-refractory prostate cancer. Semin Oncol (1999) 1.01
Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice. J Urol (1998) 1.00
Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance. Cancer Res (1998) 0.99
Expression of nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens. J Natl Cancer Inst (2000) 0.96
Tumor-associated angiogenesis in prostate cancer. Anticancer Res (1994) 0.96
The tissue matrix: cell dynamics and hormone action. Endocr Rev (1990) 0.96
Preferential adhesion of prostate cancer cells to bone is mediated by binding to bone marrow endothelial cells as compared to extracellular matrix components in vitro. Clin Cancer Res (2000) 0.95
The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth. Anticancer Res (1996) 0.94
Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. Urology (2005) 0.94
Phenotypic characterization of immortalized normal and primary tumor-derived human prostate epithelial cell cultures. Prostate (2000) 0.93
Cancer as a complex adaptive system. Med Hypotheses (1996) 0.93
Effect of prostatic inhibin peptide (PIP) on prostate cancer cell growth in vitro and in vivo. Prostate (1993) 0.92
Hormone resistance in prostate cancer. Cancer Metastasis Rev (1999) 0.91
Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study. Prostate (2000) 0.90
Galectin-3 is a nuclear matrix protein which binds RNA. Biochem Biophys Res Commun (1995) 0.89
Genetic characterization of immortalized human prostate epithelial cell cultures. Evidence for structural rearrangements of chromosome 8 and i(8q) chromosome formation in primary tumor-derived cells. Cancer Genet Cytogenet (2000) 0.89
Nuclear matrix proteins in normal and breast cancer cells. Cancer Res (1993) 0.88
Skeletal metastasis of prostate adenocarcinoma in rats: morphometric analysis and role of parathyroid hormone-related protein. Prostate (1999) 0.87
Oral etoposide in the treatment of hormone-refractory prostate cancer. Cancer (1994) 0.87
Inhibition of prostate specific antigen expression by genistein in prostate cancer cells. Int J Oncol (2000) 0.87
Preneoplastic alterations in nuclear morphology that accompany loss of tumor suppressor phenotype. J Natl Cancer Inst (1991) 0.87
Loss of cell-contact regulation and altered responses to autocrine motility factor correlate with increased malignancy in prostate cancer cells. Int J Cancer (1995) 0.86
An in vitro and in vivo study of antitumor effects of genistein on hormone refractory prostate cancer. Anticancer Res (1995) 0.85
Vitamins A and E: further clues for prostate cancer prevention. J Natl Cancer Inst (1998) 0.84
A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines. Cancer Lett (1993) 0.84
Vitamin E, alpha- and gamma-tocopherol, and prostate cancer. Semin Urol Oncol (1999) 0.83
Examination of the DNA methylation properties in nontumorigenic and tumorigenic breast epithelial cell lines. Anticancer Res (1998) 0.82
Establishment and characterization of a new human prostatic cancer cell line: DuCaP. In Vivo (2001) 0.82
4-Hydroxyphenylretinamide in the chemoprevention of cancer. Adv Pharmacol (1995) 0.82
Quality-of-life evaluation in patients receiving treatment for advanced prostate cancer. Oncol Nurs Forum (1999) 0.81
Effect of organ site on nuclear matrix protein composition. J Cell Biochem (1996) 0.81
Is dietary fat a risk factor for prostate cancer? J Natl Cancer Inst (1993) 0.80
Prostate cancer cell adhesion to quiescent endothelial cells is not mediated by beta-1 integrin subunit. Anticancer Res (2001) 0.80
Unique nuclear matrix protein alterations in head and neck squamous cell carcinomas: intermediate biomarker candidates. Otolaryngol Head Neck Surg (1996) 0.80
The Hospice Supportive Care Program: a new "transitionless" model of palliative care for patients with incurable prostate cancer. J Natl Cancer Inst (1996) 0.79
Establishment of immortalized Copenhagen rat prostate endothelial cell lines. In Vivo (1996) 0.79
A new concept in cancer care: the supportive care program. Am J Hosp Palliat Care (2001) 0.79
New concepts in studying the control of normal and cancer growth of the prostate. Prog Clin Biol Res (1987) 0.79
Etoposide in prostate cancer. Expert Opin Pharmacother (2000) 0.78
Signaling network of paclitaxel-induced apoptosis in the LNCaP prostate cancer cell line. Urology (1999) 0.78
The effect of age on the response of the detrusor to intracellular mechanical stimulus: DNA replication and the cell actin matrix. J Cell Biochem (1992) 0.78
Modifications of the intermediate filament and nuclear matrix networks by the extracellular matrix. Biochem Biophys Res Commun (1991) 0.78
The role of the nuclear matrix in cancer chemotherapy. Crit Rev Eukaryot Gene Expr (1999) 0.77
Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease. Urology (1999) 0.77
Inhibition of prostate cancer growth by 9-aminocamptothecin and estramustine. Urology (1996) 0.77
Nuclear morphometry for prediction of metastatic potential in early squamous cell carcinoma of the floor of the mouth. Arch Otolaryngol Head Neck Surg (1992) 0.76
Inhibition of prostate cancer growth by estramustine and colchicine. Prostate (1995) 0.76
Establishment of an immortalized Copenhagen rat prostate epithelial cell line. In Vivo (1996) 0.76
Modeling signal transduction in normal and cancer cells using complex adaptive systems. Med Hypotheses (1997) 0.76
Effects of extracellular matrix components and dihydrotestosterone on the structure and function of human prostate cancer cells. Prostate (1992) 0.75
The effect of amiloride on the metastatic properties of prostate cancer in the Dunning rat model. Oncol Rep (1998) 0.75
Use of bisphosphonates in the treatment of prostate cancer. Oncology (Williston Park) (2000) 0.75
The treatment of hormone refractory prostate cancer. Compr Ther (1996) 0.75
The effect of hydrazine sulfate on prostate cancer growth. Oncol Rep (1998) 0.75
The effect of castanospermine on the metastatic properties of prostate cancer cells. Anticancer Res (1998) 0.75
Immunomagnetic isolation of endothelial cells from normal rat prostate tissue. In Vivo (1995) 0.75
Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo. Anticancer Res (1994) 0.75
The study of gemcitabine in combination with other chemotherapeutic agents as an effective treatment for prostate cancer. Anticancer Res (2000) 0.75
Alterations in cellular gene expression without changes in nuclear matrix protein content. J Cell Biochem (1994) 0.75
Evidence for lectin signaling to the nuclear matrix: cellular interpretation of the glycocode. J Cell Biochem Suppl (2000) 0.75
Carboplatin-induced cell death in model prostate cancer systems. Anticancer Res (1999) 0.75
Supportive care in the patient with hormone refractory prostate cancer. Semin Urol Oncol (1997) 0.75
New treatment strategies for hormone refractory prostate cancer. Semin Urol (1995) 0.75
The isolation and characterization of epithelial cells from canine prostate. Anticancer Res (1999) 0.75
Role of the nuclear matrix in breast cancer. Cancer Treat Res (1996) 0.75
Reverse transcriptase- polymerase chain reaction (RT-PCR) to detect prostate cancer micrometastasis in the blood. Cancer Treat Res (1996) 0.75
Development of doxorubicin resistant rat prostate cancer cell lines. Anticancer Res (1998) 0.75
The use of prostate-specific antigen as a surrogate end point in the treatment of patients with hormone refractory prostate cancer. Urol Clin North Am (1997) 0.75
Recent advances in chemotherapy for advanced prostate cancer. Curr Urol Rep (2000) 0.75
A high-fat diet does not influence the growth of the Dunning R3327-H transplantable prostate adenocarcinoma. Anticancer Res (1998) 0.75
The effect of maltose tetrapalmitate (MTP) on prostate cancer growth in vivo and in vitro. Anticancer Res (1994) 0.75
A model to study c-myc and v-H-ras induced prostate cancer progression in the Copenhagen rat. Cell Mol Biol (Noisy-le-grand) (1998) 0.75
Rational use of chemotherapy. It is not just rat poison. Urol Clin North Am (1999) 0.75
Novel molecular targets for prostate cancer therapy. Semin Oncol (1999) 0.75